Analysis of the Juvenile Idiopathic Arthritis Immunization Schedule

Background: The connection between vaccination and autoimmune diseases (and rheumatic pathology in particular) is still a subject of discussions. When discussing the possibility of vaccinating rheumatic patients we should take into account the ultra high dangers that infectious diseases pose for such patients, including those that can be prevented by vaccination. We should also take into account the experience of using various vaccine types in rheumatic patients, which illustrates of their high safety profile.

Objective: Our aim was to study the immunization schedule in children with juvenile idiopathic arthritis.

Methods: The evaluation of vaccine history and other anamnestic data in juvenile idiopathic arthritis patients was based on individual medical records (individual child’s card/preventive vaccination certificate), as well as questionnaires filled by mothers.

Results: It has been determined that a significant proportion of children with vaccination schedule deviations are juvenile idiopathic arthritis patients. Almost one in four children with a confirmed rheumatic diagnosis has not been immunized against the major vaccine-preventable diseases. In one non-vaccinated group, there was a case of juvenile arthritis onset after recovering from measles. A small number of patient mothers connects the manifestation of rheumatic diseases with vaccination.

Conclusion: Violations of vaccination status in JIA patients require corrections according to the results of clinical studies and the recommendations of international experts.

1. Алексеева Е.И., Литвицкий П.Ф. Ювенильный ревматоидный артрит. Этиология. Патогенез. Клиника. Алгоритмы диагностики и лечения. Руководство для врачей, преподавателей, научных сотрудников / Под общей ред. А.А. Баранова. — М.; 2007. — С. 325–339. [Alexeeva EI, Litvitskii PF. Yuvenil’nyi revmatoidnyi artrit. Etiologiya. Patogenez. Klinika. Algoritmy diagnostiki i lecheniya. Rukovodstvo dlya vrachei, prepodavatelei, nauchnykh sotrudnikov. Ed by A.A. Baranov. Moscow; 2007. p. 325–339. (In Russ).]

2. Cassidy JT, Petty RE. Juvenile idiopathic arthritis. Textbook of pediatric rheumatology. 5th ed. Philadelphia: WB Saunders; 2005. p. 210–220.

3. Ogilvie EM, Khan A, Hubank M, et al. Specific gene expression profiles in systemic juvenile idiopathic arthritis. Arthritis Rheum. 2007;56(6):1954–1965. doi: 10.1002/art.22644.

4. Kuijk LM, Hoffman HL, Neven B, Frenkel J. Episodic autoinflammatory disorders in children. In: Cimas R, Lehman Т, editors. Handbook of systemic autoimmune disease. Elsevier; 2008. V. 6. p. 119–135.

5. Ling X, Park JL, Carroll T, et al. Plasma profiles in active systemic juvenile idiopathic arthritis: biomarkers and biological implications. Proteomics. 2010;10(24):4415–4430. doi: 10.1002/pmic.201000298.

6. Masters SL, Simon A, Aksentijevich I, Kastner DL. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu Rev Immunol. 2009;27:621–668. doi: 10.1146/annurev.immunol.25.022106.141627.

7. Mellins ED, Macaubas C, Grom AA. Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat Rev Rheumatol. 2011;7(7):416–426. doi: 10.1038/nrrheum.2011.68.

8. Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet. 2011;377(9783):2138–2149. doi: 10.1016/S0140-6736(11)60244-4.

9. Oberle EJ, Harris JG, Verbsky JW. Polyarticular juvenile idiopathic arthritis — epidemiology and management approaches. Clin Epidemiol. 2014;6:379–393. doi: 10.2147/CLEP.S53168.

10. Ярилин А.А. Основы иммунологии. Учебник. — М.: Медицина; 1999. — 608 с. [Yarilin AA. Osnovy immunologii. Uchebnik. Moscow: Meditsina; 1999. 608 p. (In Russ).]

11. Костинов М.П., Тарасова А.А. Вакцинопрофилактика пневмококковой инфекции и гриппа при аутоиммунных заболеваниях. Руководство для врачей. — М.: МДВ; 2009. —252 с. [Kostinov MP, Tarasova AA. Vaktsinoprofilaktika pnevmokokkovoi infektsii i grippa pri autoimmunnykh zabolevaniyakh. Rukovodstvo dlya vrachei. Moscow: MDV; 2009. 252 p. (In Russ).]

12. Lee K, Hall AJ. Executive summary of report on hepatitis B vaccine and putative associations with arthritis and chronic fatigue syndrome. Reports WHO. London; 2008.

13. Белов Б.С., Наумцева М.С., Тарасова Г.М., Полянская М.В. Вакцинация в ревматологии: современные аспекты // Научно-практическая ревматология. — 2014. — Т. 52. — № 6. — С. 660–668. [Belov BS, Naumtseva MS, Tarasova GM, Polyanskaya MV. Vaccination in rheumatology: Current aspects. Science-practical rheumatology. 2014;52(6):660–668. (In Russ).]

14. Current awareness. Pharmacoepidemiol Drug Saf. 2001;10(5): 467–482. doi: 10.1002/pds.550.

15. Maglione MA, Gidengil C, Das L, et al. Safety of vaccines used for routine immunization in the United States. Evidence Report/Technology Assessment No. 215 [Internet]. (Prepared by the Southern California Evidence-based Practice Center under Contract No. 290-2007-10062-I.) AHRQ Publication No. 14-E002-EF. Rockville, MD: Agency for Healthcare Research and Quality; 2014 [cited 2016 Jun 21]. Available from: http://effectivehealthcare.ahrq.gov/ehc/products/468/1930/vaccine-safety-report-140701.pdf.

16. Белов Б.С., Балабанова Р.М., Манукян С.Г., и др. Коморбидные инфекции при ревматических заболеваниях / Тезисы доклада международной конференции ревматологов. — Чимкент; 2006. — С. 17. [Belov BS, Balabanova RM, Manukyan SG, et al. Komorbidnye infektsii pri revmaticheskikh zabolevaniyakh. In: (Conference proceedings) Tezisy doklada mezhdunarodnoi konferentsii revmatologov. Chimkent; 2006. p. 17. (In Russ).]

17. Wolfe F, Mitchell DM, Sibley JT, et al. The mortality of rheumatoid arthritis. Arthritis Rheum. 1994;37(4):481–494. doi: 10.1002/art.1780370408.

18. Dougados M, Soubrier M, Antunez A, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis. 2014;73(1):62–68. doi: 10.1136/annrheumdis-2013-204223.

19. van Assen S, Agmon-Levin N, Elkayam O, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2011;70(3): 414–422. doi: 10.1136/ard.2010.137216.

20. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64(5):625–639. doi: 10.1002/acr.21641.

21. Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):e44–100. doi: 10.1093/cid/cit684.

22. Lawson EF, Trupin L, Yelin EH, Yazdany J. Reasons for failure to receive pneumococcal and influenza vaccinations among immunosuppressed patients with systemic lupus erythematosus. Semin Arthritis Rheum. 2015;44(6):666–671. doi: 10.1016/j.semarthrit.2015.01.002.

23. Вакцины для профилактики коклюша (Позиция ВОЗ) // Педиатрическая фармакология. — 2008. — Т. 5. — № 1. — С. 91–94. [Vaccines for pertussis prevention (WHO position). (editorial) Pediatric pharmacology. 2008;5(1):91–94. (In Russ).]

24. Лакоткина Е.А., Харит С.М., Черняева Т.В., Брусов Н.К. Поствакцинальные осложнения (клиника, диагностика, лечение, профилактика). Пособие для практического врача. — СПб.; 2002. — 82 c. [Lakotkina EA, Kharit SM, Chernyaeva TV, Brusov NK. Postvaktsinal’nye oslozhneniya (klinika, diagnostika, lechenie, profilaktika). Posobie dlya prakticheskogo vracha. St. Petersburg; 2002. 82 p. (In Russ).]

25. Institute of Medicine. Adverse events associated with childhood vaccine. Washington: National Academy Press; 1994. 65 p.

26. Тарасова А.А. Состояние специфического иммунитета у детей с иммунопатологическими заболеваниями, вакцинированных в рамках календаря прививок, и клинико-иммунологический эффект бактериальной и гриппозной вакцин: автореф. дис… докт. мед. наук. — Н. Новгород; 2006. — 46 с. [Tarasova AA. Sostoyanie spetsificheskogo immuniteta u detei s immunopatologicheskimi zabolevaniyami, vaktsinirovannykh v ramkakh kalendarya privivok, i kliniko-immunologicheskii effekt bakterial’noi i grippoznoi vaktsin. [dissertation abstract] N. Novgorod; 2006. 46 p. (In Russ).]

27. Тарасова А.А., Костинов М.П., Коровкина Т.И., и др. Иммунологическая эффективность и безопасность вакцинации против пневмококковой инфекции у детей с ревматическими заболеваниями // Педиатрия. Журнал им. Г.Н. Сперанского. — 2015. — Т. 94. — № 2. — С. 110–115. [Tarasova AA, Kostinov MP, Korovkina TI, et al. Immunological efficacy and safety of vaccination against pneumococcal infection in children with rheumatic diseases. Pediatriia. 2015;94(2):110–115. (In Russ).]

28. Кощеева Ю.В., Харит С.М., Калинина Н.М., и др. Особенности поствакцинального противодифтерийного иммунитета у детей с ревматическими заболеваниями / Сб. материалов по конференции: «Дни иммунологии». — СПб.; 1999. — С. 67–68. [Koshcheeva YuV, Kharit SM, Kalinina NM, et al. Osobennosti postvaktsinal’nogo protivodifteriinogo immuniteta u detei s revmaticheskimi zabolevaniyami. In: (Conference proceedings) Sb. materialov po konferentsii: «Dni immunologii». St. Petersburg; 1999. p. 67–68. (In Russ).]

29. Харит С.М. Клинико-иммунологическая характеристика вакцинального процесса у детей с иммунопатологическими заболеваниями и поражением нервной системы: автореф. дис. … докт. мед. наук. — СПб.; 2002. — 42 с. [Kharit SM. Klinikoimmunologicheskaya kharakteristika vaktsinal’nogo protsessa u detei s immunopatologicheskimi zabolevaniyami i porazheniem nervnoi sistemy. [dissertation abstract] St. Petersburg; 2002. 42 p. (In Russ).]

30. Silva CA, Terreri MT, Aikawa NE, et al. Pratica de vacinao em criancas com doencas reumaticas. Rev Bras Reumatol. 2010;50(4): 351–361. doi: 10.1590/s0482-50042010000400002.